Trial | NCT00687505  Report issue

Title

Safety Study of FP-1039 To Treat Cancer
A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    fp-1039 ...

  • Study Participants

    39
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
Study Started
Jul 31
2008
Primary Completion
May 31
2011
Study Completion
Jun 30
2011
Last Update
Dec 13
2021

Drug FP-1039

Intravenous weekly administration

1 Experimental

Single ascending doses

Criteria 

Inclusion Criteria:

Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
Male or female 18 years of age or older

Exclusion Criteria:

Presence or history of melanoma
Primary brain tumor
Presence or history of glaucoma
No Results Posted